A fungus first detected in a single U.S. patient a decade ago has quietly become one of the most closely watched pathogens in American hospitals. Candida auris was first reported in the U.S. in 2016, and for years it remained a niche concern – something infectious disease specialists tracked, but that rarely made headlines. What changed wasn’t just the number of cases. It was what those cases revealed about the limits of modern medicine.
The fungus doesn’t respond to standard treatments the way most infections do. Some strains are considered a superbug because they’re resistant to all types of medications usually used to treat fungal infections. Doctors dealing with those pan-resistant strains – meaning resistant to every available drug class – face a genuinely empty toolbox. As Melissa Nolan, an assistant professor of epidemiology and biostatistics at the University of South Carolina, described it: “If you get infected with this pathogen that’s resistant to any treatment, there’s no treatment we can give you to help combat it. You’re all on your own.”
The scale of the problem in 2026 makes that warning harder to dismiss. Clinical infections more than doubled in three years, from 2,882 in 2022 to 6,197 in 2024, according to a CDC surveillance report released June 30, 2026. The fungal infection spreading across the country has now reached a point where public health officials can no longer treat it as a regional outlier.
The Fungus Is Now Confirmed in 23 States
Despite efforts to contain its spread, 23 states, including Colorado, have already confirmed new cases this year, according to new data from the Centers for Disease Control and Prevention. The burden is not spread evenly. Texas has seen more than 700 known cases as of mid-July, while Colorado has reported 13. Michigan is close behind Texas with 503 cases of Candida auris. The concentration in large states with dense hospital networks is not a coincidence – the more patients cycling through intensive care units and long-term care facilities, the more opportunities the organism has to find a foothold.
Its widespread transmission in hospitals and long-term care facilities has posed a significant public health challenge, especially in the context of the increasing ineffectiveness of antifungal drugs. For anyone with a family member in an acute care setting in one of these high-burden states, the practical question isn’t abstract: it’s whether the facility is screening patients and taking isolation protocols seriously.
Cases Have More Than Doubled in Three Years
The CDC tracked 13,507 clinical cases during 2022 – 2024, increasing from 2,882 in 2022 to 6,197 in 2024. Part of that increase reflects improved detection. Whether that rise reflects more frequent infections or more looking is hard to settle. Reported cases are a function of effort as much as of biology: hospitals expanded testing and screening, and screening cases became nationally notifiable in 2023, each of which lifts the count independent of transmission. Screening cases – meaning the fungus is found on a patient’s skin without causing active infection – are counted separately from clinical cases but still matter, because a colonized patient can pass the organism to others.
According to the CDC’s tracking data, a total of 6,304 clinical cases of Candida auris were reported in 2024. Even accounting for expanded surveillance, the upward trend in true infections has not reversed. With 2026 data still accumulating through July, the final annual count is expected to be substantial.
It Kills a Significant Proportion of the People It Infects
A 2024 systematic review published in Medical Mycology found that overall mortality rates associated with C. auris candidemia – the bloodstream form of the infection – ranged from 29% to 62% across 37 studies. The wide band reflects differences between patient populations, geographic locations, and drug resistance profiles. No study in the review found mortality below 29%, which speaks to how lethal this organism is once it enters the bloodstream.
The organism colonizes the skin of hospitalized and long-term-care patients, usually without harm, but in the very sick it can enter the bloodstream, where infections are often fatal. The transition from silent colonization to bloodstream infection is the crux of why C. auris is so dangerous – and why early detection through screening is so critical for high-risk patients.
The Fungal Infection Is Spreading Through Hospital Surfaces and Medical Devices
Unlike many pathogens that require direct person-to-person contact, C. auris has an unusual ability to persist in the environment. It can survive on surfaces for long periods of time before spreading to patients through catheters, breathing tubes, or IVs. That durability means standard cleaning protocols that work against most hospital pathogens are often insufficient.
Patients in healthcare facilities can be asymptomatically colonized with C. auris – meaning they carry it without showing any signs of infection – and can spread it onto surfaces and objects where it can further spread to other patients. A patient who doesn’t look or feel sick can unknowingly seed a hospital room, contaminating bed rails, IV poles, and monitoring equipment for days or weeks.
This is one reason outbreaks in ICUs are so difficult to extinguish once they begin. Screening means swabbing patients to find carriers and isolating them before the organism reaches roommates and equipment – a labor-intensive process that many facilities are not yet equipped to perform at scale.
Nearly All Strains Are Already Resistant to the Go-To Antifungal Drug
Fluconazole is typically the first medication doctors reach for when treating a fungal infection. Against C. auris, it almost never works. The CDC’s Antimicrobial Resistance Laboratory Network found that 95% of isolates tested were fluconazole resistant, based on testing 8,033 clinical isolates collected across the United States during 2022 – 2023, making it the most comprehensive resistance dataset available.
The same analysis found that 15% of isolates were resistant to amphotericin B – a more powerful and toxic backup drug used when first-line options fail. Echinocandins, the third major class of antifungals and currently the most reliable treatment for C. auris, showed just 1% resistance in that dataset – but resistance to echinocandins has been documented and is considered the most dangerous trend to watch. A clinical case published in the Journal of Infectious Diseases described isolates from a lung transplant patient that were initially resistant only to fluconazole, but the terminal isolate became resistant to caspofungin and amphotericin B as well during a year of antifungal treatment.
The World Health Organization ranked Candida auris as a critical priority fungal pathogen – the highest-risk designation on its fungal pathogens list – which reflects exactly this concern about the organism’s capacity to evolve resistance during treatment. New antifungal agents are in development; fosmanogepix, for example, works by targeting a different part of the fungal cell wall, and it has shown excellent laboratory activity against pan-resistant C. auris isolates. But those drugs are not yet widely available, and the organism is not waiting.
The People at Greatest Risk Are Over 45 and Already Seriously Ill
A review of the fungus’s spread between 2022 and 2024 found that the vast majority of clinical cases – about 88% – were in people over the age of 45. A majority of patients were men and most were in acute care settings. That demographic profile matters for understanding who needs to be most vigilant – and for informing which hospital units need the most rigorous surveillance.
C. auris spreads easily in healthcare facilities and mostly affects people who are already very sick. Risk factors that put patients in this category include being on a ventilator, having a central line catheter, receiving immunosuppressive therapy such as chemotherapy or anti-rejection drugs after an organ transplant, or having recently had major surgery. In short, the people most likely to be hospitalized for other serious conditions are the same people most vulnerable to this infection.
For family members of patients in ICUs or long-term care facilities, asking whether the facility conducts active C. auris screening is a reasonable and informed question. The CDC recommends that facilities in high-prevalence areas screen new patients admitted from other healthcare settings.
What to Do Now
Candida auris is not a threat to healthy adults going about their daily lives. The risk is specific: it lives in hospitals and long-term care facilities, and it targets patients who are already medically fragile. While healthy people may be able to fight off the infection on their own, the fungus can be deadly in healthcare settings, where people are often sick and vulnerable.
If you or someone you care for is facing a hospitalization – especially in Texas, Michigan, or another high-burden state – a few concrete steps are worth knowing. Ask the care team whether C. auris screening is part of the facility’s admission protocol for patients transferred from other facilities. Confirm that the cleaning products being used in the room are EPA-registered as effective against C. auris, since not all standard hospital disinfectants kill it. And if an infection is suspected or diagnosed, ask specifically whether antifungal susceptibility testing will be done – because treatment decisions for this organism depend heavily on which drug classes the specific strain can still be treated with.
Candida auris is an urgent public health threat because of frequent multidrug resistance, high transmissibility in healthcare settings, and association with high-mortality invasive infections. The numbers in 2026 reflect a fungal infection spreading at a pace that demands attention from clinicians, policymakers, and anyone with a stake in how American hospitals manage their most vulnerable patients.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Rising Infections Put Several U.S. States on Alert Over Potentially Deadly Fungus